Close Menu

Meridian Bioscience

The tests are the eighth and ninth assays to be cleared for use on the firm's Illumigene platform and provide results in less than one hour.

The assays use specimens from symptomatic patients for the qualitative detection and differentiation of HSV-1 and HSV-2 with results generated within one hour. 

The revenue increase was driven by growth in Meridian's Diagnostics segment and particularly sales of its Illumigene product line.

Fluidigm and Meridian Bioscience led the gainers in the GenomeWeb Index for the month, while T2 Bio and PacBio's shares saw the biggest drops. 

Meridian received the CE mark for two new Illumigene molecular diagnostic tests for Chlamydia trachomatis and Neisseria gonorrhoeae.

HiberGene hopes to launch its assays, based on loop-mediated isothermal amplification, in the EU in the third quarter of this year.

Diagnostics revenues at the company jumped 5 percent organically driven in part by a 16 percent increase in sales of illumigene molecular diagnostic products.

The firm said the office will help it strengthen ties with and provide better service to it Chinese customers.

The investment bank downgraded Meridian Bioscience from a prior Market Perform rating, noting challenges to its molecular diagnostics business. 

NEW YORK (GenomeWeb) – Meridian Bioscience today said that its fiscal fourth quarter revenues declined by about 5 percent year over year as its diagnostics revenues slid 8 percent.

Pages

A bill passed by a US House of Representatives appropriations subcommittee would give scientific agencies including the National Science Foundation boosts in funding.

University of Idaho researchers model the scientific discovery process to examine the link between reproducibility and scientific truth.

Relocating USDA agencies outside of Washington, DC, may make them less effective, critics of the move tell NPR.

In PLOS this week: genes that help Borrelia burgdorferi survive in ticks, CiliaCarta collection of about 1,000 suspected cilia genes, and more.